Is Q32 Bio Inc (QTTB) a risky stock?
As of July 28, 2026, Clavix grades Q32 Bio Inc (QTTB) C- for risk, a composite score of 52 out of 100 on an A+ to F scale, which puts QTTB in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 28, 2026. Clavix regrades every trading day.
The five risk dimensions behind QTTB's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how QTTB scores on each, as of July 28, 2026.
What's moving QTTB's risk right now
Company-specific signals Clavix flags behind QTTB's current grade, drawn from recent news and filings as of July 28, 2026.
Short interest in Q32 Bio jumped sharply, meaning more traders are betting the stock will drop. The rise in bearish bets may signal doubts about the company's near-term outlook.
Q32 Bio shares climbed 81% after the company reported positive 36-week results from Part B of its Phase 2a SIGNAL-AA trial of bempikibart, an anti-IL-7R antibody for alopecia areata. Some data suggested investors consider taking profits after the big rally.
Recent QTTB news
The latest headlines Clavix ingested for Q32 Bio Inc, newest first. These feed the news-sentiment dimension of QTTB's grade.
-
Q32 Bio Inc. (NASDAQ:QTTB) saw short interest surge 234.3% to 2,263,602 shares as of July 15th, up from 677,047 shares on June 30th, with 20.4% of the company's shares now sold short.
-
The article headlines a discussion about whether Q32 Bio (QTTB) is a top momentum stock pick, but provides no substantive content beyond the introductory question.
What a C- grade means
On the Clavix A+ to F scale, QTTB's composite of 52 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell QTTB or any security. Grades are risk indicators, not predictions of return. Data may be delayed.